Beruflich Dokumente
Kultur Dokumente
Cardiac troponins
Scott M. Wells, DVM, DACVECC and Meg Sleeper, VMD, DACVIM (Cardiology)
Abstract
Objective: To review the use of cardiac troponins as biomarkers for myocardial injury in human and
veterinary medicine.
Data sources: Data sources included scientific reviews and original research publications.
Human data synthesis: Cardiac troponins have been extensively studied in human medicine. Finding an
elevated cardiac troponin level carries important diagnostic and prognostic information for humans with
cardiovascular disease. Troponin assays are used primarily to diagnose acute myocardial infarction in patients
with ischemic symptoms such as chest pain. However, elevated blood levels may be found with any cause of
myocardial injury.
Veterinary data synthesis: Several studies have shown that cardiac troponins are sensitive and specific for
myocardial damage in veterinary patients and may have utility in diagnosis and prognosis for certain disease
states. Human assays may be used in most animals due to significant homology in the troponin proteins
between species.
Conclusions: Cardiac troponins are sensitive and specific markers of myocardial injury although they do not
give any information regarding the mechanism of injury. They have redefined how acute myocardial
infarction is diagnosed in humans. Their use in the clinical management of veterinary patients is limited at this
time. Further prospective studies are warranted.
(J Vet Emerg Crit Care 2008; 18(3): 235245) doi: 10.1111/j.1476-4431.2008.00307.x
Introduction
Cardiovascular diseases are commonly encountered in
both human and veterinary medicine. Biological markers, or biomarkers, are tools used to identify high-risk
individuals, quickly and accurately diagnose disease
states, and determine treatment plans and prognoses.
While the term biomarker was first introduced in 1989,
a National Institute of Health group standardized the
definition in 2001 as a characteristic that is objectively
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.1,2
Biomarkers commonly used in the diagnosis of cardiovascular disease may include measurements taken from
blood samples, blood pressure, ECG recordings, radiographs, and echocardiograms. Cardiac troponins (cTn)
From the New England Animal Medical Center, West Bridgewater, MA
(Wells), and Assistant Professor of Cardiology, Section Chief, Cardiology,
Matthew J. Ryan Veterinary Hospital of the University of Pennsylvania,
Philadelphia, PA (Sleeper).
Address correspondence and reprint requests to:
Dr. Scott M. Wells, DVM, Veterinary Specialty Hospital of the Carolinas,
6405 Tryon Road, Cary, NC 27518.
E-mail: scottw@vshcarolinas.com
& Veterinary Emergency and Critical Care Society 2008
Physiology
Troponins are regulatory proteins that are part of the
contractile apparatus of skeletal and cardiac muscle
tissue. They are not present in smooth muscle tissue.
With the proteins actin and tropomyosin, they are part
of the thin filaments within the myofibrils and are essential for the calcium-mediated regulation of muscle
contraction. The troponin complex consists of 3 interacting and functionally distinct proteins (troponin I, T,
and C).7 Tissue-specific isoforms exist for each type of
troponin.8 Within the thin filament, tropomyosin dimers form a continuous chain along the groove of the
actin helix. The troponin complex lies at regular intervals along the filament. Tropomyosin acts to block the
myosin binding sites on actin. Each troponin protein
has specific functions that regulate muscle contraction.
235
Troponin Release
The troponin protein exists in 2 populations within the
cells. The majority of troponin is structurally bound
within the thin filaments of the contractile apparatus. A
small percentage of protein remains free in the cytosol.
This percentage is approximately 24% for cTnI and
68% for cTnT.16,17 Troponins are considered leakage
markers. Damage to cardiac myocytes resulting in loss
of membrane integrity causes the release of cTn into the
circulation. Apoptosis, a genetically programmed form
of cell death, does not result in loss of cell membrane
236
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
Cardiac troponins
Assays
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
237
Myocardial Infarction
Cardiovascular disease is the leading cause of morbidity and mortality in humans in the United States.54 The
primary role of cardiac troponin testing in human
238
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
Cardiac troponins
Prognosis
Cardiac troponins also have a role in establishing prognosis. With MI, any troponin level above the reference
range is associated with an increased risk of adverse
events in both the short- and long-term.6164 It has also
been shown that the magnitude of troponin level elevation correlates with risk of future cardiac events or
death and aids the identification of patients with greater disease severity who may benefit from more aggressive therapy.6466 In fact, the size of the infarcted area
Hypotension/hypovolemia
Renal failure
Drug toxicity (e.g., doxorubicin)
Snake envenomation
Coronary vasospasm
Inflammatory disease involving the heart (e.g., myocarditis, pericarditis)
Percutaneous coronary intervention
Pulmonary embolism and pulmonary hypertension
Infiltrative disease of the myocardium (e.g., sarcoidosis, amyloidosis)
Sympathomimetic activity (e.g., cocaine use, massive catecholamine
release such as in head trauma or stroke)
Cardiac transplantation
Chronic obstructive pulmonary disease
Ehrlichiosis
Third degree heart block
Arrhythmogenic right ventricular cardiomyopathy in Boxers
Blunt chest trauma
Subaortic stenosis
Sepsis
Aortic insufficiency jet lesions
Endurance exercise in dogs and horses
High dose isoproterenol
Trauma
Direct trauma to the heart can result in cTn elevations.
This may be secondary to mechanical injuries such as
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
239
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
Cardiac troponins
heart chamber size and cTnI level in that study. Unfortunately, as described above, cTnI comparisons between different machines are not possible and limit the
use of this data.39 Similar studies in dogs using the
cTnT assay have shown elevated levels in approximately 30% of patients with acquired heart disease, consistent with studies that show cTnI is more sensitive than
cTnT.48,51
Boxer dogs with arrhythmogenic right ventricular
cardiomyopathy are reported to have cTnI levels significantly higher than control Boxers and non-Boxers.g
This is likely due to persistent membrane leakage from
myocarditis and myofiber degeneration found with this
disease.97
Dogs with third degree atrioventricular block have
also been found to have significantly elevated cTnI
concentrations.h The underlying cause of the dysrhythmia, such as fibrosis or inflammation, or the hypoxic
damage secondary to decreased perfusion are thought
to be potential reasons.
Little research involving cardiac disease and cTn levels has been performed in horses but there are reports
of elevated cTnI levels in horses with ventricular arrhythmias. Reports of 2 horses with ventricular
tachycardia showed that 1 had a ruptured aortic jet lesion and another had severe myocardial necrosis of
unknown cause.83,98 Toxicities such as Streptococcus spp.
myositis, red maple leaf ingestion, white snakeroot
poisoning, and cantharadin intoxication from blister
beetles have been reported to cause elevated cTnI in
horses but the significance of this is unknown.i,j Additionally, cTnI elevations were noted in some endurance
horse athletes competing at the 50 and 100 mile distances, however, the significance was unclear.84
Pericardial Disease
Exercise
Many studies have reported elevated cTn levels in humans after extreme endurance exercise such as marathons and Ironman triathlons.30,31,101 A study
evaluating competitors in the 1994 Hawaii Ironman
Triathlon showed that some athletes had elevated cTnT
and cTnI levels and echocardiographic abnormalities
following the race.31 It was not determined whether
this represented temporary or long-term cardiac damage although it was believed to be transient based on
other studies involving Ironman competitors showing
echocardiographic abnormalities returning to normal
after 48 hours. Moreover, the athletes continued to
compete in these strenuous competitions. Troponin release in these cases may be from the cytosolic pool
rather than structurally bound troponin. A report on
serum chemistry alterations in Alaskan sled dogs during endurance exercise showed elevations in cTnI, with
Chemotherapy
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
241
Pulmonary Thromboembolism
Pulmonary thromboembolism (PTE) and pulmonary
hypertension cause pressure overload of the right ventricle due to increased pulmonary arterial resistance.
The resultant increase in right ventricular pressure
leads to decreased myocardial perfusion and oxygen
supply. These changes, in addition to hypoxemia
with pulmonary thromboembolism, can cause cardiac
damage and cTn leakage.70 Pulmonary embolism
has also been associated with right ventricular infarction, confounding the interpretation of elevated cTn
in these patients.102 However, patients with PTE and
elevated cTn have a worse prognosis than those without cTn elevation.70 Troponins have not yet been evaluated in veterinary patients with PTE or pulmonary
hypertension.
Feline Hyperthyroidism
Cats with hyperthyroid disease commonly have cardiovascular abnormalities. These may include tachycardia,
myocardial
hypertrophy,
hypertension,
arrhythmias, and congestive heart failure, particularly
if primary cardiomyopathy is concurrently present. In a
study of 23 hyperthyroid cats, 11 had elevated levels of
cTnI before treatment with radioactive iodine.87 Cats
with elevated cTnI had significantly thicker interventricular septums; however, this increased thickness was
still considered to be within the normal feline reference
range. Although not reaching statistical significance,
the cats with cTnI elevations also tended to have higher
T4 levels. Six months after treatment, only 3 cats still
had cTnI elevations, suggesting the resolution of continued myocyte damage in the majority of these cats.
The mechanism of troponin release was not determined
although it was speculated to result from myocardial
cell damage associated with intramural coronary ischemia or from the physiological effects of excess thyroid hormone.
Gastric Dilatation-Volvulus
Cardiovascular complications resulting from gastric dilatation-volvulus (GDV) are common. These include
shock, ischemia and reperfusion injury, and arrhythmias. It has been shown that dogs with GDV
can have myocardial degeneration, and necrosis.40 Two
studies in veterinary medicine have assessed the use of
cTn measurement to identify myocardial damage in
242
Renal Failure
Cardiac disease is a common cause of death in humans
with end-stage renal disease.78 Chronic elevations of
troponins exist in approximately 50% of patients with
chronic renal insufficiency.103 Although the exact cause
is unknown, many mechanisms for these elevations
have been proposed including silent myocardial necrosis, ventricular hypertrophy, and impaired renal clearance.76 Troponin T is more commonly associated with
elevations during renal disease with 1 study showing
82% of patients with cTnT elevations compared with
only 6% with elevated cTnI.104 However, evidence
suggests that cTnT fragments accumulate in the
bloodstream due to poor renal clearance making interpretation in these patients difficult.25 Therefore, without knowledge of baseline levels, cTnI may be more
specific for acute cardiac injury than cTnT in the face of
renal failure. Regardless of cause, elevations of troponin
I and T in patients with renal disease and patients on
hemodialysis were found to be indicators of mortality.104,105 In a veterinary study, 11 of 14 cats and 29 of 36
dogs with moderate to severe azotemia due to renal
insufficiency had elevated cTnI levels.m
Conclusion
Owing to their high sensitivity and specificity for myocardial damage, evaluation of cardiac troponin levels
has proven valuable and is firmly established in the
management of human patients with cardiac disease. In
veterinary medicine, troponin measurements have been
shown to have the potential to be sensitive indicators of
myocardial injury due to both cardiac and noncardiac
disease processes, although their role in clinical practice
remains to be determined. Perhaps future studies will
provide further evidence supporting the use of troponins in diagnosis, prognosis, and management of diseases encountered in veterinary medicine.
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
Cardiac troponins
Self-Quiz Questions
1. Which troponin may not be used to detect myocardial injury and why? Answer: Cardiac troponin C. Its
structure is homologous to an isoform of troponin C found
in skeletal muscle, therefore reducing specificity for
cardiac injury.
2. Which is true regarding cardiac troponin I assays?
(a) There exists a gold standard assay for cTnI.
(b) Each assay targets the same sequence of the
cTnI molecule.
(c) Results from different assays may be compared.
(d) The reference range is the same for all commercially available assays.
(e) Human assays may be used in veterinary
medicine.
Answer: e
3. List 10 disease states that may cause elevated cardiac
troponin levels in veterinary patients.
Answers: see Table 2.
4. An elevated cardiac troponin level indicates which
of the following:
a. Myocardial infarction.
b. Heart failure.
c. Myocardial injury.
d. Cardiac hemorrhage or inflammation.
Answer: c. Cardiac troponins indicate myocardial injury but do
not give any information regarding the mechanism of injury.
Footnotes
a
Dameron GW, Beck ML, Brandt M, et al. Tissue species specificity of two
generations of cardiac troponin T immunoassays. Clin Chem
1997;43:S192 (abstract).
Adin DB, Berger KD, Engel C, et al. Cardiac enzyme concentrations in
normal dogs and cats using a bedside analyzer. Proc 22nd ACVIM
2004;877 (abstract).
Oyama MA, Solter PF. Validation of a commercially available human
s
immunoassay (AccuTnI , Beckman Coulter Inc.) for the measurement of
canine cardiac troponin-I. Proc 21st ACVIM 2003 (abstract).
Diniz P, deMorais H, Schwartz D, et al. Cardiac troponin I in dogs
naturally infected by Ehrlichia canis. Proceedings 23rd ACVIM 2005
(abstract).
Herndon WE, Sammarco CD, Schrope D, et al. Prospective evaluation of
plasma cardiac troponin I concentration in cats with mild hypertrophic
cardiomyopathy. Proc 22nd ACVIM 2004 (abstract).
Herndon WE, Schrope D, Drobatz KJ, et al. Plasma cardiac troponin
I concentration in cats with cardiac and noncardiac causes of respiratory
distress. Proc 22nd ACVIM 2004 (abstract).
Baumwart RD, Orvalho J, Meurs KM. Elevated serum cardiac troponin
I levels in Boxer dogs with arrhythmogenic right ventricular
cardiomyopathy. Proc 24th ACVIM 2006 (abstract).
Church WM, Oyama MA, Sisson DD, et al. Troponin I elevations in dogs
with third degree atrioventricular block. Proc 24th ACVIM 2006
(abstract).
Foreman JH, Oyama MA, Tennent-Brown BS, et al. Cardiac troponin-I
plasma concentration in normal horses and in horses with arrhythmias
and toxicities. Proc 23rd ACVIM 2005 (abstract).
Holbrook TC, Panciera RJ. Biochemical evidence of cardiac injury in
horses with cantharidin toxicosis. Proc 24th ACVIM 2006 (abstract).
References
1. Biomarkers Definitions Working Group.. Biomarkers and surrogate end-points: preferred definitions and conceptual framework.
Clin Pharmacol Ther 2001; 69:8995.
2. Ramachandran SV. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;
113:23352362.
3. Adams JE III, Bodor GS, Davila-Roman VG, et al. Cardiac
troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88:101106.
4. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac
troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med 1996; 335:13331341.
5. Fredericks S, Merton GK, Lerena MJ, et al. Cardiac troponins and
creatine kinase content of striated muscle in common laboratory
animals. Clin Chim Acta 2001; 304:6574.
6. OBrien PJ, Landt Y, Ladenson JH. Differential reactivity of cardiac and skeletal muscle from various species in a cardiac
troponin I immunoassay. Clin Chem 1997; 43:23332338.
7. Kittleson MD, Kienle RD. Small Animal Cardiovascular Medicine. St. Louis, MO: Mosby Inc.; 1998, p. 16.
8. Filatov VL, Katrukha AG, Bulargina TV, et al. Troponin: structure,
properties, and mechanism of functioning. Biochemistry (Moscow) 1999; 64:11551174.
9. Schreier T, Kedes L, Gahlmann R. Cloning, structural analysis,
and expression of the human slow twitch skeletal muscle/cardiac
troponin C gene. J Biol Chem 1990; 265(212):4753.
10. Goldmann BU, Christenson RH, Hamm CW, et al. Implications of
troponin testing in clinical medicine. Curr Control Trials Cardiovasc Med 2001; 2:7584.
11. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the
detection of cardiac injury. Can Med Assoc J 2005; 173(10):1191
1202.
12. Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin-I is not
expressed in fetal and healthy or diseased adult human skeletal
muscle tissue. Clin Chem 1995; 41:17101715.
13. Maass AH, Leinwand LA. Mechanisms of the pathogenesis of
troponin T-based familial hypertrophic cardiomyopathy. Trends
Cardiovasc Med 2003; 13(6):232237.
14. Kimura A, Harada H, Park J, et al. Mutations in the cardiac
troponin I gene associated with hypertrophic cardiomyopathy.
Nat Genet 1997; 16:379382.
15. Huang X, Pi Y, Lee KJ, et al. Cardiac troponin I gene knockout: a
mouse model of myocardial troponin I deficiency. Circ Res 1999;
84:18.
16. Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients
with reperfused and nonreperfused myocardial infarction. Am J
Cardiol 1991; 67:13601367.
17. Adams JE III, Schechtman KB, Landt Y, et al. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994; 40:12911295.
18. Kostin S, Pool L, Elsasser A, et al. Myocytes die by multiple
mechanisms in failing human hearts. Circ Res 2003; 92:715724.
19. Jaffe AS, Landt Y, Parvin CA, et al. Comparative sensitivity of
cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction. Clin Chem 1996; 42:1770
1776.
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
243
244
43. Apple FS, Wu AH, Jaffe AS. European society of cardiology and
American college of cardiology guidelines for redefinition of
myocardial infarction: how to use existing assays clinically and
for clinical trials. Am Heart J 2002; 144:981986.
44. Lum G, Solarz D, Farney L. False positive cardiac troponin results
in patients without acute myocardial infarction. Lab Med 2006;
37(9):546550.
45. Rishniw M, Barr SC, Simpson KW, et al. Cloning and sequencing
of the canine and feline cardiac troponin I genes. Am J Vet Res
2004; 65:5358.
46. Sleeper MM, Clifford CA, Laster LL. Cardiac troponin I in the
normal dog and cat. J Vet Intern Med 2001; 15:501503.
47. Phillips W, Giguere S, Franklin RP, et al. Cardiac troponin I in
pastured and race-training thoroughbred horses. J Vet Intern Med
2003; 17:597599.
48. DeFrancesco TC, Atkins CE, Keene BW, et al. Prospective clinical
evaluation of serum cardiac troponin T in dogs admitted to a
veterinary teaching hospital. J Vet Intern Med 2002; 16:553557.
49. Herndon WE, Kittleson MD, Sanderson K, et al. Cardiac troponin
I in feline hypertrophic cardiomyopathy. J Vet Intern Med 2002;
16:558564.
50. Spratt DP, Mellanby RJ, Drury N, et al. Cardiac troponin I: evaluation of a biomarker for the diagnosis of heart disease in the
dog. J Small Anim Pract 2005; 46:139145.
51. Tarducci A, Abate O, Borgarelli M, et al. Serum values of cardiac
troponin-T in normal and cardiomyopathic dogs. Vet Res Comm
2004; 28:385388.
52. Oyama MA, Sisson DD. Cardiac troponin-I concentration in dogs
with cardiac disease. J Vet Intern Med 2004; 18:831839.
53. Burgener IA, Kovacevic A, Mauldin N, et al. Cardiac troponins as
indicators of acute myocardial damage in dogs. J Vet Intern Med
2006; 20:277283.
54. American Heart Association. Heart Disease and Stroke
Statistics: 2005 Update. Dallas, TX: American Heart Association;
2005.
55. Antman E, Bassand J, Klein W, et al. Myocardial infarction redefined a consensus document of The Joint European Society of
Cardiology/American College of Cardiology committee for the
redefinition of myocardial infarction: the Joint European Society
of Cardiology/American College of Cardiology Committee. J Am
Coll Cardiol 2000; 36:959969.
56. Collinson PO, Stubbs PJ. Are troponins confusing? Heart 2003;
89:12851287.
57. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial
infarction and coronary deaths in the World Health Organization
MONICA Project: registration procedures, event rates, and casefatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583612.
58. Tsung JS, Tsung SS. Creatine kinase isoenzymes in extracts of
various human skeletal muscles. Clin Chem 1986; 32:15681570.
59. Rajappa M, Sharma A. Biomarkers of cardiac injury: an update.
Angiology 2005; 56:677691.
60. Kontos MC, Fritz LM, Anderson FP, et al. Impact of the troponin
standard on the prevalence of acute myocardial infarction. Am
Heart J 2003; 146:446452.
61. Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room
triage of patients with acute chest pain by means of rapid testing
for cardiac troponin T or troponin I. N Engl J Med 1997; 337
(23):16481653.
62. Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997; 95:20532059.
63. Stubbs P, Collinson P, Moseley D, et al. Prognostic significance of
admission troponin T concentrations in patients with myocardial
infarction. Circulation 1996; 94:12911297.
64. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific
troponin I levels to predict the risk of mortality in patients with
acute coronary syndromes. N Engl J Med 1996; 335(18):1342
1349.
65. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients
with unstable coronary artery disease who benefit from longterm antithrombotic protection. Fragmin in Unstable Coronary
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
Cardiac troponins
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
xorubicin: comparison with clinical heart disease in a retrospective analysis. Vet Comp Oncol 2004; 2:142156.
Connolly DJ, Guitian J, Neiger R. Serum troponin I levels in
hyperthyroid cats before and after treatment with radioactive
iodine. J Feline Med Surg 2005; 7:289300.
Feng X, Taggart P, Hall L, et al. Limited additional release of
cardiac troponin I and T in isoproterenol-treated Beagle dogs
with cardiac injury. Clin Chem 2005; 51:13051307.
Velmahos GC, Karaiskakis M, Salim A, et al. Normal electrocardiography and serum troponin I levels preclude the presence of
clinically significant blunt cardiac injury. J Trauma 2003; 54:45
50;discussion 5051.
Fernandes CJ, Akamine N, Knobel E. Cardiac troponin: a new
serum marker of myocardial injury in sepsis. Intens Care Med
1999; 25:11651168.
Morrow D. Cardiac-specific troponins beyond ischemic heart
disease, In: Wu AHB. ed. Cardiac Markers, 2nd edn. Totowa, NJ:
Humana Press Inc.; 2003, pp. 149170.
Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed
myocyte cell death. J Clin Invest 1995; 96:22472259.
Fox PR, Sisson D, Moise NS. Textbook of Canine and Feline Cardiology, 2nd edn. Philadelphia, PA: W.B. Saunders Company;
1999, pp. 211212.
Perna ER, Macin SM, Canella JPC, et al. Ongoing myocardial
injury in stable severe heart failure: value of cardiac troponin T
monitoring for high-risk patient identification. Circulation 2004;
110:23762382.
Maron BJ, Wolfson JK, Epstein SE, et al. Intramural (small vessel) coronary artery disease in hypertrophic cardiomyopathy.
J Am Coll Cardiol 1986; 8:545557.
Krams R, Kofflard MJM, Duncker DJ, et al. Decreased coronary
flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998;
97:230233.
Basso C, Fox PR, Meurs KM, et al. Arrhythmogenic right ventricular cardiomyopathy causing sudden cardiac death in Boxer
dogs. Circulation 2004; 109:11801185.
Schwarzwald CC, Hardy J, Buccellato M. High cardiac troponin I
serum concentration in a horse with multiform ventricular
tachycardia and myocardial necrosis. J Vet Intern Med 2003;
17:364368.
Brandt RR, Filzmaier K, Hanrath P. Circulating cardiac troponin I
in acute pericarditis. Am J Cardiol 2001; 87:13261328.
Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in
plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49(2):248
252.
Chen Y, Serfass RC, Mackey-Bojack SM, et al. Cardiac troponin T
alterations in myocardium and serum of rats after stressful,
prolonged intense exercise. J Appl Physiol 2000; 88(5):1749
1755.
Pruszczyk P, Szulc M, Horszczaruk G, et al. Right ventricular
infarction in a patient with acute pulmonary embolism and normal coronary arteries. Arch Intern Med 2003; 163:11101111.
Freda BJ, Tang WH, Van Lente F, et al. Cardiac troponins in renal
insufficiency: review and clinical implications. J Am Coll Cardiol
2002; 40:20652071.
Apple FS, Murakami MM, Pearce LA, et al. Predictive value of
cardiac troponin I and T for subsequent death in end-stage renal
disease. Circulation 2002; 106:29412945.
Stolear JC, Georges B, Shita A, et al. The predictive value of cardiac troponin T measurements in subjects on regular haemodialysis. Nephrol Dial Transplant 1999; 14(8):19611967.
Antman EM. Decision making with cardiac troponin tests. N
Engl J Med 2002; 346(26):2080.
& Veterinary Emergency and Critical Care Society 2008, doi: 10.1111/j.1476-4431.2008.00307.x
245